1-7 of 7
Jeremy Barton
Close
Sort by
Journal Articles

A Phase 1-2 Dose-Escalation and Cohort- Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1 and MNK2, in Patients with Hematological Malignancies

Ajay K. Gopal, MD, Rod Ramchandren, MD, Nashat Y. Gabrail, Manish R Patel, MD, Ding Wang, MDPhD, Langdon L Miller, MD, Vikas Goel, PhD, Gary G Chiang, PhD, Kevin R Webster, PhD, Sam Sperry, PhD, Debra T Vallner, PhDMBA, Cara Casseday, BSc MBA, Jeremy Barton, MBBS
Journal: Blood
Blood (2017) 130 (Supplement 1): 4624.
https://doi.org/10.1182/blood.V130.Suppl_1.4624.4624
Published: 2017
Journal Articles

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30 + hematologic malignancies

Clinical Trials & Observations
Nancy L. Bartlett, Anas Younes, Matthew H. Carabasi, Andres Forero, Joseph D. Rosenblatt, John P. Leonard, Steven H. Bernstein, R. Gregory Bociek, Jennie M. Lorenz, Bruce W. Hart, Jeremy Barton
Journal: Blood
Blood (2008) 111 (4): 1848–1854.
https://doi.org/10.1182/blood-2007-07-099317
Published: 2008
Journal Articles

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Andres Forero-Torres, MD, STeven H. Bernstein, MD, Ajay Gopal, MD, Francine Foss, MD, John P. Leonard, MD, Joseph D. Rosenblatt, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD, Elliot Epner, MD, Francisco J. Hernandez-Ilizaliturri, MD, STephen J. Proctor, MD, Pauline Brice, MD, Herve Tilly, MD, Corinne Haioun, MD, Mats Jerkeman, MD, Andre Bosly, MD, Alessandro M. Gianni, MD, Harald Holte, MD, Premini Mahendra, MD, Lutz Uharek, MD, Jennie Lorenz, Jeremy Barton, MD, Eric Sievers, MD
Journal: Blood
Blood (2006) 108 (11): 2718.
https://doi.org/10.1182/blood.V108.11.2718.2718
Published: 2006
Journal Articles

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Madeleine Duvic, MD, Youn Kim, MD, Sunil Reddy, MD, Andres Forero-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie Worobec, MD, Neil Korman, MD, Timothy Kuzel, MD, Kimberly Bohjanen, MD, Karen Flessland, Jeremy Barton, MD, Eric Sievers, MD
Journal: Blood
Blood (2006) 108 (11): 2733.
https://doi.org/10.1182/blood.V108.11.2733.2733
Published: 2006
Journal Articles

SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Andres Forero-Torres, MD, Steven H. Bernstein, MD, Ajay K. Gopal, MD, Francine Foss, MD, John P. Leonard, MD, Joseph D. Rosenblatt, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD, Elliott Epner, MD, Francisco J. Hernandez-Illizaliturri, MD, Stephen J. Proctor, MD, Pauline Brice, MD, Harve Tilly, MD, Corinne Haioun, MD, Mats Jerkeman, MD, Andre Bosly, MD, Jennie M. Lorenz, Jeremy Barton, MD
Journal: Blood
Blood (2005) 106 (11): 3356.
https://doi.org/10.1182/blood.V106.11.3356.3356
Published: 2005
Journal Articles

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Madeleine Duvic, MD, Joy Kunishige, MD, Youn H. Kim, MD, Andres Foreno-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie M. Worobec, MD, Francine Foss, MD, Karen Flessland, Jeremy Barton, MD
Journal: Blood
Blood (2005) 106 (11): 4802.
https://doi.org/10.1182/blood.V106.11.4802.4802
Published: 2005
Journal Articles

SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30 + Malignancies.

Kevin J. Hamblett, Jeremy Barton, Charles G. Cerveny, Jamie B. Andreyka, Kim M. Kissler, Nicole M. Okeley, Ivan Stone, May K. Sutherland, Michael M. Sun, Peter D. Senter, Alan F. Wahl, Nathan C. Ihle
Journal: Blood
Blood (2005) 106 (11): 610.
https://doi.org/10.1182/blood.V106.11.610.610
Published: 2005